SPECIALTY QUANTITY LIMIT PROGRAM

TASIGNA (nilotinib HCI)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the prevention/treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Tasigna (nilotinib HCl) 50 mg capsule	120 capsules per 30 days	Pediatric patients with newly diagnosed Ph+ CML-CP or resistant or intolerant Ph+ CML-CP: 230 mg/m² orally twice daily • rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg) Adult patients: • Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily • Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily
Tasigna (nilotinib HCl) 150 mg capsule	120 capsules per 30 days	
Tasigna (nilotinib HCl) 200 mg capsule	120 capsules per 30 days	

^{*}CML: chronic myeloid leukemia; CML-AP: advanced phase; CML-CP: chronic phase; Ph+: Philadelphia chromosome positive

III. REFERENCES

1. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of